Kineta, Inc.
Index- P/E- EPS (ttm)-3.00 Insider Own1.20% Shs Outstand10.86M Perf Week-46.31%
Market Cap41.72M Forward P/E- EPS next Y- Insider Trans4.39% Shs Float0.18M Perf Month-53.75%
Income-32.00M PEG- EPS next Q- Inst Own22.60% Short Float / Ratio14.87% / 0.96 Perf Quarter-75.28%
Sales4.80M P/S8.69 EPS this Y82.20% Inst Trans-9.66% Short Interest0.03M Perf Half Y-71.69%
Book/sh0.50 P/B6.02 EPS next Y- ROA-107.10% Target Price- Perf Year-58.29%
Cash/sh0.61 P/C4.97 EPS next 5Y- ROE-263.30% 52W Range2.94 - 17.43 Perf YTD-48.50%
Dividend- P/FCF- EPS past 5Y37.80% ROI-102.20% 52W High-81.24% Beta0.06
Dividend %- Quick Ratio2.20 Sales past 5Y-0.80% Gross Margin- 52W Low11.19% ATR0.71
Employees40 Current Ratio2.20 Sales Q/Q-12.50% Oper. Margin- RSI (14)24.01 Volatility24.93% 12.42%
OptionableYes Debt/Eq0.00 EPS Q/Q67.90% Profit Margin- Rel Volume0.56 Prev Close3.01
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume27.74K Price3.27
Recom2.00 SMA20-44.56% SMA50-49.42% SMA200-67.77% Volume1,900 Change8.64%
Mar-08-23 06:30AM
Mar-06-23 06:30AM
Mar-01-23 06:30AM
Kineta, Inc., a clinical stage biotechnology company, develops immunotherapies for oncology, neuroscience, and biodefense. It serves private, government, and industry partners. The company has strategic partnerships with Pfizer, Genentech, Wellcome, and Samsung Biologics Co., Ltd. Kineta, Inc. was formerly known as Lecura, Inc. The company was incorporated in 2007 and is based in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bartoszek Raymond J.DirectorDec 30Buy6.225,00031,1259,956Jan 04 04:14 PM
Bartoszek Raymond J.DirectorDec 30Buy6.222,00112,4561,001Jan 04 04:14 PM